Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3002815 in healthy subjects
NCT03148431Phase 1Terminated
- Sponsor
- Eli Lilly and Company
- Start
- May 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing LY3002815 with Placebo (2 arms). Primary endpoint: Serious Adverse Events at 85 days. Started May 2017; status: terminated.
02
Drugs
LY3002815
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03148431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03148431.